English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

ACKNOWLEDGMENTS REFERENCES • Omadacycline (OMC), the first aminomethylcycline antibiotic to reach late-stage clinical development, is a semisynthetic derivative of the tetracyclines that exhibits activity against Gram-positive and Gram-negative aerobes, anaerobes, and atypical bacteria1 • In the Omadacycline in Acute Skin and Skin Structure Infections Study (OASIS-1, NCT02378480), intravenous to oral OMC demonstrated non-inferiority to intravenous to oral linezolid (LZD) for the treatment of ABSSSI with comparable safety in the general population.2 In the OASIS-2 study (NCT02877927), oralonly administration of OMC demonstrated non-inferiority to oral LZD for the treatment of ABSSSI with comparable safety in the general population3 • The incidence and severity of ABSSSI have increased in recent years4 – ABSSSIs include cellulitis, erysipelas, wound infections, and major cutaneous abscesses – Skin and soft tissue infections are the most common cause for hospital admissions among intravenous drug using (IVDU) patients5 • As IVDU is a major risk factor for hepatitis C viral (HCV) infection,6 we assessed whether IVDU or HCV status had any effect on the efficacy or safety of OMC relative to LZD in patients from OASIS-1

open forum infectious diseases

Efficacy and Safety of Omadacycline in Intravenous Drug Using (IVDU) and Hepatitis C-Positive (HCV+) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis from the OASIS Trial